CD19 Monoclonal Antibody

Code: CSB-MA004888A1m

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Raised in: Mouse

Application: ELISA, WB, IHC, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P15391

Target Names

CD19

Alternative Names

CD19; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; Differentiation antigen CD19; T-cell surface antigen Leu-12; CD antigen CD19

Raised in

Mouse

Species Reactivity

Human

Immunogen

Recombinant Human CD19 protein (20-291AA)

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

IgG2b

Clone No.

4C6G1

Purification Method

>95%, Protein A purified

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Tested Applications

ELISA, WB, IHC, FC

Recommended Dilution

Application	Recommended Dilution
WB	1:1000-1:5000
IHC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

Western Blot
Positive WB detected in: Raji whole cell lysate
All lanes: CD19 antibody at 1:2000
Secondary
Goat polyclonal to Mouse IgG at 1/10000 dilution
Predicted band size: 61 kDa
Observed band size: 95 kDa
IHC image of CSB-MA004888A1m diluted at 1:100 and staining in paraffin-embedded human tonsil tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
IHC image of CSB-MA004888A1m diluted at 1:100 and staining in paraffin-embedded human spleen tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.
Overlay histogram showing Raji cells stained with CSB-MA004888A1m (red line) at 1:50. The cells were incubated in 1x PBS /10% normal goat serum to block non-specific protein-protein interactions followed by primary antibody for 1 h at 4°C. The secondary antibody used was FITC goat anti-mouse IgG(H+L) at 1/200 dilution for 1 h at 4°C. Isotype control antibody (green line) was used under the same conditions. Acquisition of >10,000 events was performed.

Description

The production of the CD19 monoclonal antibody began with immunization of mouse & isolation of splenocytes. A Recombinant Human CD19 protein (20-291AA) was injected into the mouse and later its blood was screened for the next step. The splenocytes were then isolated for in vitro hybridoma production. At the same time, the myeloma cells were prepared. Myeloma cells and isolated splenocytes were fused together to form hybridomas with hybridoma technology. Next, hybridomas were screened and cloned. Finally, the CD19 monoclonal antibody was produced and validated in ELISA, WB, IHC, FC.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Functions as coreceptor for the B-cell antigen receptor complex (BCR) on B-lymphocytes. Decreases the threshold for activation of downstream signaling pathways and for triggering B-cell responses to antigens. Activates signaling pathways that lead to the activation of phosphatidylinositol 3-kinase and the mobilization of intracellular Ca(2+) stores. Is not required for early steps during B cell differentiation in the blood marrow. Required for normal differentiation of B-1 cells. Required for normal B cell differentiation and proliferation in response to antigen challenges. Required for normal levels of serum immunoglobulins, and for production of high-affinity antibodies in response to antigen challenge.

Gene References into Functions

diffuse large B cell lymphoma lacking CD19 or PAX5 expression were more likely to have mutant TP53. PMID:28484276
The impairment of Bregs and CD19+/BTLA+ cells could play an important pathogenic role in multiple sclerosis (MS). PMID:27412504
Inhibition of Akt signaling during ex vivo priming and expansion gives rise to CD19CAR T cell populations that display comparatively higher antitumor activity PMID:28331616
CD19-specific triplebody SPM-1 mediated potent lysis of cancer-derived B cell lines and primary cells from patients with various B-lymphoid malignancies. PMID:27825135
The increase in CD19+CD24+CD27+ Bregs was closely associated with fasting insulin secretion. PMID:28440417
The preclinical activity, safety and PK profile support clinical investigation of MGD011 (MGD011 is a CD19 x CD3 DART bispecific protein )as a therapeutic candidate for the treatment of B-cell malignancies PMID:27663593
this study shows that CD19 isoforms enable resistance to adoptive cellular immunotherapy PMID:28441264
Anti-CD19-chimeric antigen receptors T cells synergistically exerted collaborative cytotoxicity against primary double-hit lymphoma cells with anti-CD38-chimeric antigen receptors T cells. PMID:28595585
Two infants with relapsed, refractory B-cell acute lymphoblastic leukemia went into complete remission after being treated with CD19-targeting CAR T cells derived from an unmatched donor PMID:28193774
These data provide proof-of-principle for the view that newly generated Ab-secreting cells can acquire a mature plasma cell phenotype that is accompanied by loss of CD19 expression at an early stage of differentiation and that aging is not an obligate requirement for a CD19(neg) state to be established. PMID:28490574
Results indicate the strong efficacy of FLAG-tagged CD19 CAR-T cells in solid and hematological cancer models. PMID:28410137
The histological observations suggested that the patients represent diverse cases of NHL like mature B-cell type, mature T-cell type and high grade diffuse B-cell type NHL. The findings indicate that patients with NHL may also be analyzed for status of PAX5, CD19 and ZAP70, and their transcriptional and post-translational variants for the differential diagnosis of NHL and therapy. PMID:27748274
The frequencies of CD19+CD24hiCD38hi B-regulatory lymphocyte were significantly increased in children with beta-thalassemia. PMID:26852663
a CD45+/CD19 - cell population in bone marrow aspirates correlated with the clinical outcome of patients with mantle cell lymphoma. PMID:25739938
CD19 is required for TLR9-induced B-cell activation. Hence CD19/PI3K/AKT/BTK is an essential axis integrating BCRs and TLR9 signaling in human B cells. PMID:26478008
High anti-EBV IgG levels in Crohn's disease are associated with 5-aminosalicylic acid treatment, tonsillectomy, and decrease of CD19(+) cells. PMID:25914477
We propose that CD81 enables the maturation of CD19 and its trafficking to the membrane by regulating the exit of CD19 from the ER to the pre-Golgi compartment PMID:25739915
we outline our approach to nonviral gene transfer using the Sleeping Beauty system and the selective propagation of CD19-specific CAR(+) T cells on AaPCs PMID:25591810
We demonstrate that this motif plays a role in the maturation and recycling of CD19 but in a CD81-independent manner. PMID:26111452
Studies indicate that anti-CD19 and anti-CD33 bispecific antibodies showed anticancer activity. PMID:25883042
The synaptic recruitment of lipid rafts is dependent on CD19-PI3K module and cytoskeleton remodeling molecules. PMID:25979433
gene deficiency results in severe lung disease in French patient PMID:24684239
propose a multilayer model of plasma cell (PC) memory in which CD19(+) and CD19(-) PC represent dynamic and static components, respectively, permitting both adaptation and stability of humoral immune protection PMID:25573986
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcgammaRIIb and CD19. PMID:24828435
Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation. PMID:24418477
A lower primary CD24(hi) CD27(+) CD19(+) B cells may be an immunologic aspect of new-onset SLE that may be a useful tool to evaluate lupus activity and monitor the response to therapy. PMID:24286662
higher percentage of CD19+ cells in patients with acute appendicitis; decreases after appendectomy PMID:24375063
CD20 and CD19 targeting vectors induce activating stimuli in resting B lymphocytes, which most likely renders them susceptible for lentiviral vector transduction. PMID:24244415
Latently infected cells from patients with multiple sclerosis, treated with natalizumab, initiate differentiation to CD19+ cells that favor growth of JC polyomavirus. PMID:24664166
This inhibitory function of FcgammaRIIB in impairing the spatial-temporal colocalization of BCR and CD19 microclusters in the B cell immunological synapse may help explain the hyper-reactive features of systemic lupus erythematosus PMID:24790152
Considering that the CD19 complex regulates the events following antigen stimulation, the change in CD19 complex detected in transient hypogammaglobulinemia of infancy may be related to insufficiency of antibody production. PMID:22820757
CD19 emerged as a powerful predictor of event-free and overall survival in CNS diffuse large B-cell lymphomas and Burkitt lymphomas PMID:24501214
these data demonstrate that CD19 and CD32b differentially inhibit B cell expansion and plasma cell differentiation, depending on the nature of the activating stimuli, when engaged with monospecific Abs. PMID:24442430
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. PMID:23193950
CD19 is expressed very early in B-cell development and is a good target for antibody therapy in lymphoblastic leukemia. PMID:23277329
The resulting CD19(high)/CD19(low) B-cell ratio increased markedly in the milk-tolerant group. PMID:22563781
Use of c-Myc transgenic mice deficient in CD19 expression leads to identification of a c-Myc:CD19 regulatory loop that positively influences B cell transformation and lymphoma progression. PMID:22826319
Results obtained through a large cohort of European caucasian patients with systemic sclerosis do not support the contribution of CD19, CD20, CD22, CD24 variants to the genetic susceptibility. PMID:21961844
Data indicate that among MDS cases, CD15+ and CD19+ cell TLs were positively correlated, and PBL TL was was not associated with hTERT genotype. PMID:21635204
Studies showed the qualitative and quantitative expression of four target surface antigens, CD19, CD20, CD22, and CD33, for which MoAbs are currently available for clinical use, in ALL. PMID:21348573
Data show that CD45+CD19- MCL-ICs play a role in the drug resistance of MCL, and this drug resistance was largely due to quiescent properties with enriched ABC transporters. PMID:21599592
A missense mutation of CD19 in the conserved tryptophan 41 in immunoglobulin superfamily domain resulted in antibody deficiency. PMID:21330302
Data suggest that CD19 and CD33 are present on the surface of the leukemic cell lines such that they can be connected by a single sctb molecule. PMID:21081841
CD23 and CD19 are important factors that associated with serum total IgE in the pathogenesis of allergic rhinitis. PMID:20359104
binding sites for CD19 and CD16 have a role in antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells PMID:21339041
Heterozygous loss of CD19 causes some changes in the naive B-cell compartment, but overall in vivo B-cell maturation or humoral immunity is not affected. PMID:20445561
Altered CD19/CD22 balance in Egyptian children and adolescents with systemic lupus erythematosus. PMID:20726320
The CD27(+) B-cell population was found to highly express CXCR3 in chronic hepatitis C (CHC), thus suggesting that the CD27(+) B-cell population was recruited from peripheral blood to the inflammatory site of the liver of CHC. PMID:20377416
Aberrant expression of CD19 in acute myeloblastic leukemia with t(8;21) involves a poised chromatin structure and PAX5. PMID:20208555
Studies indicate taht B lymphocytes proliferated when approximately 100 antigen receptors per cell, 0.03 percent of the total, were coligated with CD19. PMID:20164433